Eisai Co., Ltd. (4523.T)

6,455.00 +82.00 (+1.29%) At close: 02:51PM JST

Eisai Co., Ltd.

4-6-10, Koishikawa
Bunkyo-ku
Tokyo 112-8088
Japan
81 3 3817 3700
https://www.eisai.co.jp

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 11,067

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Haruo Naito	CEO, Representative Corporate Officer & Director	N/A	N/A	1947
Mr. Gary Hendler	Senior VP & President of EMEA Region	N/A	N/A	1966
Ms. Yanhui Feng	Senior Vice President	N/A	N/A	1972
Dr. Nadeem Sarwar Ph.D.	President	N/A	N/A	N/A
Mitsuru Shomon	VP & CFO	N/A	N/A	N/A
Makoto Hoketsu	VP & Chief Information Officer	N/A	N/A	N/A
Ms. Sayoko Sasaki	Vice President of Corporate Communications & ESG	N/A	N/A	1968
Mr. Teiji Kimura	Head of Academia Industry Alliance, DHBL Office	N/A	N/A	1963
Mr. Tatsuyuki Yasuno	Senior VP & President of Americas Region	N/A	N/A	1968
Mr. Shohei Kanazawa	VP & President of Asia and Latin America Region - API Solutions	N/A	N/A	1965

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.

Description

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Corporate governance

Eisai Co., Ltd.’s ISS governance QualityScore as of 1 July 2024 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 7; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.